NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) News Today $0.57 -0.02 (-2.54%) (As of 09:41 AM ET) Add Compare Share Share Today's Range$0.58▼$0.6050-Day Range$0.48▼$0.6352-Week Range$0.46▼$10.39Volume153,643 shsAverage Volume678,803 shsMarket Capitalization$4.17 millionP/E RatioN/ADividend YieldN/APrice Target$46.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosafinance.yahoo.com - October 3 at 9:41 AMKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Yearsfinance.yahoo.com - September 21 at 8:05 AMKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosafinance.yahoo.com - September 18 at 8:35 AMKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosafinance.yahoo.com - September 14 at 10:02 AMKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27finance.yahoo.com - September 1 at 9:40 AMKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseasesfinance.yahoo.com - August 29 at 5:13 PMIs Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysisfinance.yahoo.com - August 24 at 1:09 PMKiora Pharmaceuticals Shares Up 18% on Patents Covering Ocular Delivery of Moleculesmarketwatch.com - August 23 at 3:20 PMWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?markets.businessinsider.com - August 23 at 10:14 AMKiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitisfinance.yahoo.com - August 23 at 10:14 AMKiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Programfinance.yahoo.com - August 22 at 5:34 PMKiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conferencefinance.yahoo.com - August 16 at 8:46 AMKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progressfinance.yahoo.com - August 8 at 11:07 AMKiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatmentfinance.yahoo.com - August 3 at 10:12 AMBiotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directorsfinance.yahoo.com - August 1 at 6:35 PMWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?investorplace.com - July 21 at 9:08 AMKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Diseasefinanznachrichten.de - July 5 at 8:54 AMKiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Diseasefinance.yahoo.com - July 5 at 8:54 AM8-K: KIORA PHARMACEUTICALS INCmarketwatch.com - June 22 at 6:32 PMLife Science Investor Forum Agenda Announced for June 22ndfinance.yahoo.com - June 20 at 11:23 AMKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201finanznachrichten.de - June 15 at 7:43 AMKiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201finance.yahoo.com - June 15 at 7:43 AMKiora Pharmaceuticals to Present at Upcoming Investor Conferencesfinance.yahoo.com - June 14 at 10:07 AMKiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Optionfinance.yahoo.com - June 6 at 7:32 PMKiora Heralds Public Offeringbaystreet.ca - June 2 at 12:36 PMWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 49% Today?investorplace.com - June 2 at 10:09 AMRecap: Kiora Pharmaceuticals Q1 Earningsmsn.com - May 9 at 3:03 PMKiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatmentsfinance.yahoo.com - May 9 at 10:02 AMKiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meetingfinance.yahoo.com - May 1 at 7:50 AMKiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blindfinance.yahoo.com - April 27 at 6:43 PMKiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defectsfinance.yahoo.com - April 26 at 10:14 AMKiora Pharmaceuticals, Inc.: Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Boardfinanznachrichten.de - April 21 at 10:51 AMInherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Boardfinance.yahoo.com - April 21 at 10:51 AMKiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseasesfinance.yahoo.com - April 17 at 9:26 AMKiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meetingfinance.yahoo.com - March 30 at 10:02 AMAnalyst Ratings for Kiora Pharmaceuticalsmarkets.businessinsider.com - March 24 at 7:19 PMMaxim Group Reaffirms Their Buy Rating on Kiora Pharmaceuticals (KPRX)markets.businessinsider.com - March 11 at 4:09 PMKiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meetingfinance.yahoo.com - March 10 at 7:51 AMKiora Pharmaceuticals Director Awarded $31K Worth of Stock Optionsbenzinga.com - March 8 at 7:10 PMAnalysts Offer Insights on Healthcare Companies: Tempest Therapeutics (TPST), Kiora Pharmaceuticals (KPRX) and Indaptus Therapeutics (INDP)markets.businessinsider.com - February 8 at 9:37 AMKiora Pharmaceuticals Soars 43% After IND Application Approval for KIO-101marketwatch.com - February 7 at 1:13 PMKiora Soars on IND Approval for KIO-101 Eye Dropsmsn.com - February 7 at 1:13 PMmarketbeat.com - February 7 at 9:51 AMKiora Pharma Shares Rise 55% After IND Application Approval for HIO-101marketwatch.com - February 7 at 8:13 AMKiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseasesfinance.yahoo.com - February 7 at 8:12 AMKiora’s stock rallies as eye drop treatment moves into mid-stage clinical trialfinance.yahoo.com - February 7 at 8:12 AMKiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capitalfinance.yahoo.com - February 3 at 9:26 AMKiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Websitefinance.yahoo.com - January 9 at 7:30 AMmarketbeat.com - January 3 at 1:31 PMmarketbeat.com - January 3 at 1:15 PM Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Media Mentions By Week KPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPRX News Sentiment▼1.440.70▲Average Medical News Sentiment KPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPRX Articles This Week▼31▲KPRX Articles Average Week Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lixte Biotechnology News Today BiondVax Pharmaceuticals News Today TransCode Therapeutics News Today Protagenic Therapeutics News Today Agile Therapeutics News Today 60 Degrees Pharmaceuticals News Today PainReform News Today Synaptogenix News Today Adial Pharmaceuticals News Today Universe Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:KPRX) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.